{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:43:17Z","timestamp":1744681397730},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,12,27]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The loop diuretic drug furosemide is widely used for the treatment of edema in\nvarious conditions, such as pulmonary, cardiac and hepatic edema, as well as cardiac infarction. Furosemide,\ndue to its poor water solubility and low bioavailability after oral administration of conventional\ndosage form, is categorized as class IV in the biopharmaceutical classification system.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In the case of furosemide, this release profile is responsible for various physiological problems,\nacute diuresis being the most serious. This adverse effect can be circumvented by the modified\nrelease of furosemide from tablet formulations compared to those forms designed for immediate release.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p> In this report, a D-optimal combined experimental design was applied for the development of\nfurosemide containing bilayer and compression coated tablets, aiming at lowering the drug\u2019s burst release\nin the acidic environment of the stomach. A D-optimal combined design was selected in order to\ninclude all requirements in one design with many levels for the factors examined. The following responses\nwere selected as the ones reflecting better criteria for the desired drug release: dissolution at 120\nmin (30-40%), 300 min (60-70%) and 480 min &gt;95%. The new formulations, suggested by the Doptimal\ncombined design, incorporated different grades of Eudragit \u00ae polymers (Eudragit\u00ae E100 and\nEudragit\u00ae L100-55), lactose monohydrate and HPMC K15M. The dissolution profile of furosemide\nfrom these systems was probed via in vitro dissolution experiments in buffer solutions simulating the\npH of the gastrointestinal tract.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The results indicate that the use of Eudragit\u00ae E100 in conjunction with lactose monohydrate\nled to 21.32-40.85 % drug release, in the gastric medium, in both compression-coated and bilayer tablets.\nThis is lower than the release of the mainstream drug Lasix\u00ae (t=120 min, 44.5% drug release), implying\nlonger gastric retention and drug waste minimization.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Furosemide\u2019s release in the intestinal environment, from compression coated tablets incorporating\nEudragit\u00ae L100-55 and HPMC K15M in the inner core or one of the two layers of the bilayer\ntablets, was delayed, compared to Lasix\u00ae<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201816666191029130324","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T10:33:10Z","timestamp":1572431590000},"page":"931-939","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations"],"prefix":"10.2174","volume":"16","author":[{"given":"Marilena","family":"Vlachou","sequence":"first","affiliation":[{"name":"Section of Pharmaceutical Technology, School of Health Sciences, National and Kapodistrian University of Athens, Athens 15784, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Siamidi","sequence":"additional","affiliation":[{"name":"Section of Pharmaceutical Technology, School of Health Sciences, National and Kapodistrian University of Athens, Athens 15784, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis","family":"Dotsikas","sequence":"additional","affiliation":[{"name":"Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens 15784, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1152\/ajprenal.00476.2015","volume":"310","author":"Huang X.","year":"2016","unstructured":"Huang X.; Dorhout Mees E.; Vos P.; Hamza S.; Braam B.; Everything we always wanted to know about furosemide but were afraid to ask. Am J Physiol Ren Physiol 2016,310,958-971","journal-title":"Am J Physiol Ren Physiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/polym9120643","volume":"8","author":"Kumar S.","year":"2016","unstructured":"Kumar S.; Kumar M.A.; Preformulation study of furosemide. Der Pharmacia Lettre 2016,8,214-222","journal-title":"Der Pharmacia Lettre"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ph6091094","volume":"6","author":"Pacifici G.M.","year":"2013","unstructured":"Pacifici G.M.; Clinical pharmacology of furosemide in neonates: A review. Pharmaceuticals (Basel) 2013,6(9),1094-1129","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","volume":"13","author":"Oh S.W.","year":"2015","unstructured":"Oh S.W.; Han S.Y.; Loop diuretics in clinical practice. Electrolyte Blood Press 2015,13(1),17-21","journal-title":"Electrolyte Blood Press"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/0110-5558.76441","volume":"1","author":"Patel R.C.","year":"2010","unstructured":"Patel R.C.; Keraliya R.A.; Patel M.M.; Patel N.M.; Formulation of furosemide solid dispersion with micro crystalline cellulose for achieve rapid dissolution. J Adv Pharm Technol Res 2010,1(2),180-189","journal-title":"J Adv Pharm Technol Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1211\/0022357011775721","volume":"53","author":"Terao T.","year":"2001","unstructured":"Terao T.; Matsuda K.; Shouji H.; Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. J Pharm Pharmacol 2001,53(4),433-440","journal-title":"J Pharm Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0885328203017003557","volume":"17","author":"Vlachou M.","year":"2003","unstructured":"Vlachou M.; Papa\u00efoannou G.; Preparation and characterization of the inclusion complex of furosemide with hydroxypropyl-\u03b2-cyclodextrin. J Biomater Appl 2003,17(3),197-206","journal-title":"J Biomater Appl"},{"key":"ref=8","first-page":"94","volume":"2","author":"Deshmukh A.","year":"2010","unstructured":"Deshmukh A.; Nakhat P.; Yeole P.; Formulation and in-vitro evaluation of self microemulsifying drug delivery system (SMEDDS) of Furosemide. Der Pharmacia Lettre 2010,2,94-106","journal-title":"Der Pharmacia Lettre"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.15171\/apb.2015.055","volume":"5","author":"Sambaraj S.","year":"2015","unstructured":"Sambaraj S.; Ammula D.; Nagabandi V.; Furosemide loaded silica-lipid hybrid Microparticles: Formulation development, in vitro and ex vivo evaluation. Adv Pharm Bull 2015,5(3),403-409","journal-title":"Adv Pharm Bull"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.matdes.2018.11.036","volume":"162","author":"Hai T.","year":"2019","unstructured":"Hai T.; Wana X.; Yu D.G.; Wang K.; Yang Y.; Liu Z.P.; Electrospun lipid-coated medicated nanocomposites for an improved drug sustained-release profile. Mater Des 2019,162,70-79","journal-title":"Mater Des"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cej.2018.09.096","volume":"356","author":"Liu X.","year":"2019","unstructured":"Liu X.; Yang Y.; Yu D.G.; Zhu M.J.; Min Z.; Williams G.R.; Tunable zero-order drug delivery systems created by modified triaxial electrospinning. Chem Eng J 2019,356,886-894","journal-title":"Chem Eng J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.carbpol.2018.09.061","volume":"203","author":"Yang Y.","year":"2019","unstructured":"Yang Y.; Li W.; Yu D.G.; Wang G.; Williams G.R.; Zhang Z.; Tunable drug release from nanofibers coated with blank cellulose acetate layers fabricated using tri-axial electrospinning. Carbohydr Polym 2019,203,228-237","journal-title":"Carbohydr Polym"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2478\/acph-2020-0010","volume":"70","author":"Vlachou M.","year":"2019","unstructured":"Vlachou M.; Geraniou E.; Samidi A.; Modified release of furosemide from Eudragits and poly(ethylene oxide)-based matrices and dry-coated tablets. Acta Pharm 2019,70(1),49-61","journal-title":"Acta Pharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/clc.4960091107","volume":"9","author":"Brodin L.\u00c5.","year":"1986","unstructured":"Brodin L.\u00c5.; Jogestrand T.; Larsen F.F.; Tedner B.; Walldius G.; Effects of furosemide and slow-release furosemide on thoracic fluid volumes. Clin Cardiol 1986,9(11),561-564","journal-title":"Clin Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1208\/pt010434","volume":"1","author":"Efentakis M.","year":"2000","unstructured":"Efentakis M.; Koutlis A.; Vlachou M.; Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech 2000,1(4)","journal-title":"AAPS PharmSciTech"},{"key":"ref=16","first-page":"935","volume":"2","author":"Jain D.","year":"2010","unstructured":"Jain D.; Verma S.; Shukla S.B.; Jain A.K.; Jain P.; Yadav P.; Formulation and evaluation of gastroretentive tablets of Furosemide (Evaluation based on drug release kinetics and factorial designs). J Chem Pharm Res 2010,2,935-978","journal-title":"J Chem Pharm Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0378-5173(99)00303-8","volume":"195","author":"Aceves J.M.","year":"2000","unstructured":"Aceves J.M.; Cruz R.; Hernandez E.; Preparation and characterization of Furosemide-Eudragit controlled release systems. Int J Pharm 2000,195(1-2),45-53","journal-title":"Int J Pharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jsps.2017.04.002","volume":"25","author":"Ibrahim M.A.","year":"2017","unstructured":"Ibrahim M.A.; Abou El Ela A.E.S.F.; Optimized furosemide taste masked orally disintegrating tablets. Saudi Pharm J 2017,25(7),1055-1062","journal-title":"Saudi Pharm J"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2325-9604.1000159","volume":"5","author":"Vlachou M.","year":"2016","unstructured":"Vlachou M.; Siamidi A.; Konstantinidou S.; Dotsikas Y.; Optimization of controlled release matrix formulation of melatonin via experimental design. J Pharm Drug Deliv Res 2016,5,1-5","journal-title":"J Pharm Drug Deliv Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15406\/ppij.2017.05.00115","volume":"5","author":"Vlachou M.","year":"2017","unstructured":"Vlachou M.; Siamidi A.; Efentakis M.; Investigation of a novel \u201ctablets in capsule\u201d theophylline formulation system for modified release. Pharm Pharmacol Int J 2017,5,1-7","journal-title":"Pharm Pharmacol Int J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1055\/s-0042-121491","volume":"67","author":"Vlachou M.","year":"2017","unstructured":"Vlachou M.; Siamidi A.; Diamantidi E.; Iliopoulou A.; Papanastasiou I.; Ioannidou V.; Kourbeli V.; Foscolos A.S.; Vocat A.; Cole S.T.; Karalis V.; Kellici T.; Mavromoustakos T.; \n                        In vitro controlled release from solid pharmaceutical formulations of two new adamantane aminoethers with antitubercular activity (I). Drug Res (Stuttg) 2017,67(8),447-450","journal-title":"Drug Res (Stuttg)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1055\/s-0043-114012","volume":"67","author":"Vlachou M.","year":"2017","unstructured":"Vlachou M.; Siamidi A.; Spaneas D.; Lentzos D.; Ladia P.; Anastasiou K.; Papanastasiou I.; Foscolos A.S.; Georgiadis M.O.; Karalis V.; Kellici T.; Mavromoustakos T.; \n                        In vitro controlled release of two new tuberculocidal adamantane aminoethers from solid pharmaceutical formulations (II). Drug Res (Stuttg) 2017,67(11),653-660","journal-title":"Drug Res (Stuttg)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/ijms18081641","volume":"18","author":"Vlachou M.","year":"2017","unstructured":"Vlachou M.; Papamichael M.; Siamidi A.; Fragouli I.; Afroudakis P.A.; Kompogennitaki R.; Dotsikas Y.; Comparative In vitro controlled release studies on the chronobiotic hormone melatonin from cyclodextrins-containing matrices and Cyclodextrin: Melatonin complexes. Int J Mol Sci 2017,18(8),1641","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jddst.2017.11.019","volume":"44","author":"Vlachou M.","year":"2018","unstructured":"Vlachou M.; Tragou K.; Siamidi A.; Kikionis S.; Chatzianagnostou A.L.; Mitsopoulos A.; Ioannou E.; Roussis V.; Tsotinis A.; Modified in vitro release of the chronobiotic hormone melatonin from matrix tablets based on the marine sulfated polysaccharide ulvan. J Drug Deliv Sci Technol 2018,44,41-48","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1567201815666180914095701","volume":"16","author":"Vlachou M.","year":"2019","unstructured":"Vlachou M.; Kikionis S.; Siamidi A.; Tragou K.; Kapoti S.; Ioannou E.; Roussis V.; Tsotinis A.; Fabrication and characterization of electrospun nanofibers for the modified release of the chronobiotic hormone melatonin. Curr Drug Deliv 2019,16(1),79-85","journal-title":"Curr Drug Deliv"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0169-7439(94)00076-X","volume":"30","author":"de Aguiar X.P.F.","year":"1995","unstructured":"de Aguiar X.P.F.; Bourguignon B.; Khots M.S.; Massart D.L.; Phan-Than-Luu R.; D-optimal designs. Chemom Intell Lab Syst 1995,30,199-210","journal-title":"Chemom Intell Lab Syst"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.microc.2011.06.022","volume":"99","author":"Malenovi\u0107 A.","year":"2011","unstructured":"Malenovi\u0107 A.; Dotsikas Y.; Ma\u0161kovi\u0107 M.; Jan\u010di\u0107-Stojanovi\u0107 B.; Ivanovi\u0107 D.; Medenica M.; Desirability-based optimization and its sensitivity analysis for the perindopril and its impurities analysis in a microemulsion LC system. Microchem J 2011,99,454-460","journal-title":"Microchem J"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1211\/0022357011775721","volume":"53","author":"Terao T.","year":"2001","unstructured":"Terao T.; Matsuda K.; Shouji H.; Improvement in site-specifc intestinal absorption of furosemide by Eudragit L100-55. J Pharm Pharmacol 2001,53,433-440","journal-title":"J Pharm Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2478\/acph-2018-0035","volume":"68","author":"Han M.","year":"2018","unstructured":"Han M.; Yu Q.; Liu X.; Hu F.; Yuan H.; Preparation and characterization of a novel aqueous dispersion for enteric coating of pantoprazole sodium pellets. Acta Pharm 2018,68(4),441-455","journal-title":"Acta Pharm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jsps.2017.04.002","volume":"25","author":"Ibrahim M.A.","year":"2017","unstructured":"Ibrahim M.A.; Abou El Ela A.E.S.F.; Optimized furosemide taste masked orally disintegrating tablets. Saudi Pharm J 2017,25(7),1055-1062","journal-title":"Saudi Pharm J"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejpb.2015.11.015","volume":"98","author":"Vo A.Q.","year":"2016","unstructured":"Vo A.Q.; Feng X.; Morott J.T.; Pimparade M.B.; Tiwari R.V.; Zhang F.; Repka M.A.; A novel floating controlled release drug delivery system prepared by hot-melt extrusion. Eur J Pharm Biopharm 2016,98,108-121","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.24218\/vjpps.2016.19","volume":"1","author":"Vlachou M.","year":"2016","unstructured":"Vlachou M.; Siamidi A.; Pareli I.; Zampakola A.; Konstantinidou S.; An Account of modified release of melatonin from compression-coated, uncoated and bilayer tablets. J Pharm Pharm Sci 2016,1,10-14","journal-title":"J Pharm Pharm Sci"},{"key":"ref=33","first-page":"271","volume":"3","author":"Gavate N.T.","year":"2013","unstructured":"Gavate N.T.; Gondkar S.B.; Saudagar R.B.; Multilayer tablet: A new trend in solid dosage forms. World J Pharm Pharm Sci 2013,3,271-284","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fphar.2015.00144","volume":"6","author":"Momin M.M.","year":"2015","unstructured":"Momin M.M.; Kane S.; Abhang P.; Formulation and evaluation of bilayer tablet for bimodal release of venlafaxine hydrochloride. Front Pharmacol 2015,6,144","journal-title":"Front Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.2174\/1567201815666180123094320","volume":"15","author":"Marzan A.L.","year":"2018","unstructured":"Marzan A.L.; Tabassum R.; Jahan B.; Asif M.H.; Reza H.M.; Kazi M.; Alshehri S.M.; de Matas M.; Shariare M.H.; Preparation and characterization of stable nanosuspension for dissolution rate enhancement of furosemide: A quality by design (QbD) approach. Curr Drug Deliv 2018,15(5),672-685","journal-title":"Curr Drug Deliv"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/01621459.2015.1136632","volume":"111","author":"Goos Y.P.","year":"2016","unstructured":"Goos Y.P.; Jones B.; Syafitri U.; I-optimal design of mixture experiments. J Am Stat Assoc 2016,111,899-911","journal-title":"J Am Stat Assoc"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jddst.2016.08.003","volume":"35","author":"Khlibsuwan R.","year":"2016","unstructured":"Khlibsuwan R.; Pongjanyakul T.; Chitosan-clay matrix tablets for sustained-release drug delivery: Effect of chitosan molecular weight and lubricant. J Drug Deliv Sci Technol 2016,35,303-313","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jms.2016.10.020","volume":"332","author":"Cismesia A.P.","year":"2017","unstructured":"Cismesia A.P.; Nicholls G.R.; Polfer N.C.; Amine vs. carboxylic acid protonation in ortho-, meta-, and para-aminobenzoic acid: An IRMPD spectroscopy study. J Mol Spectrosc 2017,332,79-85","journal-title":"J Mol Spectrosc"},{"key":"ref=39","first-page":"525-533","author":"Rowe R.C.","year":"2006","unstructured":"Rowe R.C.; Sheskey P.J.; Owen S.C.; Polymethacrylates. In\nHandbook of Pharmaceutical Excipients, 5th ed.; American Pharmaceutical\nAssociation and Pharmaceutical Press: London, 2006,525-533"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1021\/mp300282f","volume":"9","author":"Guzm\u00e1n M.L.","year":"2012","unstructured":"Guzm\u00e1n M.L.; Manzo R.H.; Olivera M.E.; Eudragit E100 as a drug carrier: The remarkable affinity of phosphate ester for dimethylamine. Mol Pharm 2012,9(9),2424-2433","journal-title":"Mol Pharm"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/adhm.201500872","volume":"5","author":"Jin M.","year":"2016","unstructured":"Jin M.; Yu D.G.; Wang X.; Geraldes C.F.; Williams G.R.; Bligh S.W.; Electrospun contrast-agent-loaded fibers for colon-targeted MRI. Adv Healthc Mater 2016,5(8),977-985","journal-title":"Adv Healthc Mater"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1021\/acs.molpharmaceut.6b00197","volume":"13","author":"Jin M.","year":"2016","unstructured":"Jin M.; Yu D.G.; Geraldes C.F.G.C.; Williams G.R.; Bligh S.W.; Theranostic fibers for simultaneous imaging and drug delivery. Mol Pharm 2016,13(7),2457-2465","journal-title":"Mol Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.jconrel.2017.03.077","volume":"259","author":"Yu D.G.","year":"2017","unstructured":"Yu D.G.; Li H.P.; Yang C.; Li J.J.; Wang Q.; Williams G.R.; Double-pulsatile release core-shell fibers fabricated using modified tri-axial electrospinning. J Control Release 2017,259,e24-e25","journal-title":"J Control Release"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.11.022","volume":"386","author":"Mour\u00e3o S.C.","year":"2010","unstructured":"Mour\u00e3o S.C.; da Silva C.; Bresolin T.M.B.; Serra C.H.R.; Porta V.; Dissolution parameters for sodium diclofenac-containing hypromellose matrix tablet. Int J Pharm 2010,386(1-2),201-207","journal-title":"Int J Pharm"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.carbpol.2017.06.075","volume":"174","author":"Wang Q.","year":"2017","unstructured":"Wang Q.; Yu D.G.; Zhang L.L.; Liu X.K.; Deng Y.C.; Zhao M.; Electrospun hypromellose-based hydrophilic composites for rapid dissolution of poorly water-soluble drug. Carbohydr Polym 2017,174,617-625","journal-title":"Carbohydr Polym"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2018.08.016","volume":"292","author":"Yu D.G.","year":"2018","unstructured":"Yu D.G.; Li J.J.; Williams G.R.; Zhao M.; Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review. J Control Release 2018,292,91-110","journal-title":"J Control Release"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T16:03:07Z","timestamp":1579708987000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176285\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666191029130324","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}